Abstract
A pharmacokinetics and metabolism study was conducted in eight healthy human volunteers. After oral administration of [14C]eplerenone (EP) at a dose of 100 mg per person as an aqueous solution, blood, saliva, breath, urine, and fecal samples were collected at various time points. All matrices were analyzed for total radioactivity and/or for EP and its open-lactone-ring form (EPA). EP was well absorbed, and a mean EP Cmax of 1.72 μg/ml was achieved 1.2 h postdose. After the Cmax, plasma concentrations of EP declined with a half-life of 3.0 h. Plasma concentrations of EPA were much lower than EP concentrations, and the area under the plasma-concentration time curve (AUC) for EPA was only 4% of the EP AUC. Plasma protein binding was moderate (33-60%) but concentration-dependent over the therapeutic concentration range. EP and its metabolites did not preferentially partition into the red blood cells and blood concentrations of total radioactivity were lower than plasma concentrations. Approximately 66.6% and 32.0% of the radioactive dose were excreted in urine and feces, respectively. The majority of urinary and fecal radioactivity was due to metabolites, indicating extensive metabolism of EP. The major metabolic pathways were 6β- and/or 21-hydroxylation and 3-keto reduction. There was no evidence for any alteration of the 9,11-epoxide ring or the methyl ester. As a percentage of dose, the primary metabolic products excreted in urine and feces included 6β-hydroxy-EP (6β-OHEP) (32.0%), 6β,21-OHEP (20.5%), 21-OHEP (7.89%), and 2α,3β,21-OHEP (5.96%). The amounts of the other metabolites excreted were less than 5% each.
Footnotes
-
↵1 Abbreviations used are: EP, eplerenone; OHEP, hydroxy-eplerenone; HIV, human immunodeficiency virus; LSC, liquid scintillation counting; EPA, open-lactone ring (hydrolyzed) form of eplerenone; LC/MS-MS, liquid chromatography/tandem mass spectrometry; HPLC, high performance liquid chromatography; NMR, nuclear magnetic resonance spectroscopy; APCI, atmospheric pressure chemical ionization; COSY, correlation spectroscopy; AUC, area under the plasma-concentration time curve.
- Received May 5, 2003.
- Accepted July 23, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|